EEG Patterns Predicting Clobazam Response in Refractory Status Epilepticus in Adults

Hammer H., Ebert B., Jensen H.S., Jensen A.A.: Functional characterization of the 1,5-benzodiazepine clobazam and its major active metabolite N-desmethylclobazam at human GABA(A) receptors expressed in Xenopus laevis oocytes. PLoS One, 2015 Mar 23; 10 (3): e0120239. doi: 10.1371/journal.pone.0120239. PMID: 25798598; PMCID: PMC4370687. HammerH. EbertB. JensenH.S. JensenA.A. Functional characterization of the 1,5-benzodiazepine clobazam and its major active metabolite N-desmethylclobazam at human GABA(A) receptors expressed in Xenopus laevis oocytes PLoS One 2015 Mar 23 10 3 e0120239 10.1371/journal.pone.0120239 25798598 PMC4370687 Open DOISearch in Google Scholar

Huddart R., Leeder J.S., Altman R.B., Klein T.E.: PharmGKB summary: clobazam pathway, pharmacokinetics. Pharmacogenet Genomics, 2018, 28: 110–115. doi: 10.1097/FPC.0000000000000327. PMID: 29517622; PMCID: PMC5914180. HuddartR. LeederJ.S. AltmanR.B. KleinT.E. PharmGKB summary: clobazam pathway, pharmacokinetics Pharmacogenet Genomics 2018 28 110 115 10.1097/FPC.0000000000000327 29517622 PMC5914180 Open DOISearch in Google Scholar

Madžar D., Geyer A., Knappe R.U., Gollwitzer S., Kuramatsu J.B., Gerner S.T. et al.: Effects of clobazam for treatment of refractory status epilepticus. BMC Neurol., 2016, 16: 202. doi: 10.1186/s12883-016-0724-y. PMID: 27769254; PMCID: PMC5073816. MadžarD. GeyerA. KnappeR.U. GollwitzerS. KuramatsuJ.B. GernerS.T. Effects of clobazam for treatment of refractory status epilepticus BMC Neurol. 2016 16 202 10.1186/s12883-016-0724-y 27769254 PMC5073816 Open DOISearch in Google Scholar

Maille J.M., Hanna S.S., Shah D.N.: Addition of clobazam successfully treating drug resistant seizures in Heidenhain variant Creutzfeldt Jakob disease: A case report. Epilepsy Behav. Rep., 2023, 21: 100585. doi: 10.1016/j.ebr.2023.100585. PMID: 36698381; PMCID: PMC9867951. MailleJ.M. HannaS.S. ShahD.N. Addition of clobazam successfully treating drug resistant seizures in Heidenhain variant Creutzfeldt Jakob disease: A case report Epilepsy Behav. Rep. 2023 21 100585 10.1016/j.ebr.2023.100585 36698381 PMC9867951 Open DOISearch in Google Scholar

Marawar R., Basha M., Mahulikar A., Desai A., Suchdev K., Shah A.: Updates in Refractory Status Epilepticus. Crit Care Res Pract, 2018; 2018: 9768949. doi: 10.1155/2018/9768949. PMID: 29854452; PMCID: PMC5964484. MarawarR. BashaM. MahulikarA. DesaiA. SuchdevK. ShahA. Updates in Refractory Status Epilepticus Crit Care Res Pract 2018 2018 9768949 10.1155/2018/9768949 29854452 PMC5964484 Open DOISearch in Google Scholar

Sankar R.: GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam. CNS Drugs, 2012, 26: 229–44. doi: 10.2165/11599020-000000000-00000. PMID: 22145708. SankarR. GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam CNS Drugs 2012 26 229 44 10.2165/11599020-000000000-00000 22145708 Open DOISearch in Google Scholar

Sivakumar S., Ibrahim M., Parker D. Jr, Norris G., Shah A., Mohamed W.: Clobazam: An effective add-on therapy in refractory status epilepticus. Epilepsia, 2015, 56: e83–9. doi: 10.1111/epi.13013. Epub 2015 May 12. PMID: 25963810. SivakumarS. IbrahimM. ParkerD.Jr NorrisG. ShahA. MohamedW. Clobazam: An effective add-on therapy in refractory status epilepticus Epilepsia 2015 56 e83 9 10.1111/epi.13013 Epub 2015 May 12. 25963810 Open DOISearch in Google Scholar

Storustovu S.I., Ebert B.: Pharmacological characterization of agonists at delta-containing GABAA receptors: functional selectivity for extra synaptic receptors is dependent on the absence of gamma2. J. Pharmacol. Exp. Ther., 2006, 316: 1351–1359. StorustovuS.I. EbertB. Pharmacological characterization of agonists at delta-containing GABAA receptors: functional selectivity for extra synaptic receptors is dependent on the absence of gamma2 J. Pharmacol. Exp. Ther. 2006 316 1351 1359 Search in Google Scholar

Thome-Souza S., Klehm J., Jackson M., Kadish N.E., Manganaro S., Fernández I.S. et al.: Clobazam higher-evening differential dosing as an add-on therapy in refractory epilepsy. Seizure, 2016, 1–6. doi 10.1016/j.seizure.2016.05.014. Epub 2016 May 27. PMID: 27281712. Thome-SouzaS. KlehmJ. JacksonM. KadishN.E. ManganaroS. FernándezI.S. Clobazam higher-evening differential dosing as an add-on therapy in refractory epilepsy Seizure 2016 1 6 10.1016/j.seizure.2016.05.014 Epub 2016 May 27. 27281712 Open DOISearch in Google Scholar

Vasquez A., Gaínza-Lein M., Sánchez Fernández I., Abend N.S., Anderson A., Brenton J.N. et al.: Pediatric Status Epilepticus Research Group (pSERG). Hospital Emergency Treatment of Convulsive Status Epilepticus: Comparison of Pathways From Ten Pediatric Research Centers. Pediatr. Neurol., 2018, 86: 33–41. doi: 10.1016/j.pediatrneurol.2018.06.004. Epub 2018 Jul 11. PMID: 30075875. VasquezA. Gaínza-LeinM. Sánchez FernándezI. AbendN.S. AndersonA. BrentonJ.N. Pediatric Status Epilepticus Research Group (pSERG). Hospital Emergency Treatment of Convulsive Status Epilepticus: Comparison of Pathways From Ten Pediatric Research Centers Pediatr. Neurol. 2018 86 33 41 10.1016/j.pediatrneurol.2018.06.004 Epub 2018 Jul 11. 30075875 Open DOISearch in Google Scholar